Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Asset Writedowns and Impairment (2019 - 2024)

Lifecore Biomedical, Inc. \De\ (LFCR) has 7 years of Asset Writedowns and Impairment data on record, last reported at $1.3 million in Q2 2023.

  • For Q2 2023, Asset Writedowns and Impairment fell 97.18% year-over-year to $1.3 million; the TTM value through Feb 2024 reached $46.1 million, down 39.98%, while the annual FY2023 figure was $1.3 million, 98.34% down from the prior year.
  • Asset Writedowns and Impairment reached $1.3 million in Q2 2023 per LFCR's latest filing, up from -$1.3 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $46.1 million in Q2 2022 and bottomed at -$1.3 million in Q1 2023.
  • Average Asset Writedowns and Impairment over 5 years is $7.7 million, with a median of $124500.0 recorded in 2020.
  • The widest YoY moves for Asset Writedowns and Impairment: up 47656.72% in 2021, down 102.16% in 2021.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $2.0 million in 2019, then tumbled by 96.65% to $67000.0 in 2020, then surged by 47656.72% to $32.0 million in 2021, then skyrocketed by 44.04% to $46.1 million in 2022, then crashed by 97.18% to $1.3 million in 2023.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $1.3 million in Q2 2023, -$1.3 million in Q1 2023, and $46.1 million in Q2 2022.